Upregulation of Nei-Like DNA Glycosylase 3 Predicts Poor Prognosis in Hepatocellular Carcinoma
Background. Accumulating evidence has suggested that Nei-like DNA glycosylase 3 (NEIL3) is associated with human tumors. However, there are few studies on the role of NEIL3 in hepatocellular carcinoma (HCC). The aim of this study was to investigate the expression profile of NEIL3 and its clinical re...
Gespeichert in:
| Veröffentlicht in: | Journal of oncology 2021, Vol.2021, p.1301671-11 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 11 |
|---|---|
| container_issue | |
| container_start_page | 1301671 |
| container_title | Journal of oncology |
| container_volume | 2021 |
| creator | Wu, Dongyu Zhang, Guangcong Ma, Jiamei Wu, Hongfen Xiong, Ju Huang, Xiaoxi Tian, Yuanyuan Deng, Taozhi Han, Xiangyang Sun, Xiaoning Xiang, Tian Yu, Xiangnan Jiang, Xuemei |
| description | Background. Accumulating evidence has suggested that Nei-like DNA glycosylase 3 (NEIL3) is associated with human tumors. However, there are few studies on the role of NEIL3 in hepatocellular carcinoma (HCC). The aim of this study was to investigate the expression profile of NEIL3 and its clinical relevance in HCC. Materials and Methods. A total of 130 HCC and corresponding nontumor tissues were collected to perform immunohistochemistry (IHC). The clinical relevance and prognostic value of NEIL3 in HCC were analyzed by the chi-square test, Kaplan–Meier analysis, the Cox proportional hazard model, and nomogram. Results. IHC showed that the NEIL3 protein level was remarkably upregulated in tumor tissues compared with nontumor tissues (fold change = 1.24; P |
| doi_str_mv | 10.1155/2021/1301671 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8519696</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A683555239</galeid><sourcerecordid>A683555239</sourcerecordid><originalsourceid>FETCH-LOGICAL-c504t-e02f04f32a925e9776392cdf02666192aeb5c8be6cabff246d18426a64d7b773</originalsourceid><addsrcrecordid>eNp9ks9vFCEYhonR2Fq9eTYkXkx0LL8ZLiabVVuTTe2hXiUMA1vqLGxhRrP_vUx2rdVDT0B48nx54QXgJUbvMeb8lCCCTzFFWEj8CBxj0cqmZRw9vrc_As9KuUFIMKTEU3BEmeCKIXYMvn_bZreeBjOGFGHy8MKFZhV-OPjxYgHPhp1NZTeY4iCFl9n1wY4FXqaU6ymtYyqhwBDhuduaMVk3DFWV4dJkG2LamOfgiTdDcS8O6wm4-vzpannerL6efVkuVo3liI2NQ8Qj5ikxinCnpBRUEdt7RIQQWBHjOm7bzglrOu8JEz1uGRFGsF52UtIT8GGv3U7dxvXWxTGbQW9z2Ji808kE_e9NDNd6nX7qlmMllKiCNwdBTreTK6PehDLHMdGlqWjCW0ox4pJU9PV_6E2acqzpZooIpoSgf6m1GZwO0ac6185SvagDW8Yklg9TLeWcE6oq9W5P2ZxKyc7fBcNIzx3Qcwf0oQMVf3X_Me7gP59egbd74DrE3vwKD-t-A-s_tns</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2582649663</pqid></control><display><type>article</type><title>Upregulation of Nei-Like DNA Glycosylase 3 Predicts Poor Prognosis in Hepatocellular Carcinoma</title><source>Wiley Online Library Open Access</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><source>EZB Electronic Journals Library</source><source>PubMed Central Open Access</source><creator>Wu, Dongyu ; Zhang, Guangcong ; Ma, Jiamei ; Wu, Hongfen ; Xiong, Ju ; Huang, Xiaoxi ; Tian, Yuanyuan ; Deng, Taozhi ; Han, Xiangyang ; Sun, Xiaoning ; Xiang, Tian ; Yu, Xiangnan ; Jiang, Xuemei</creator><contributor>Granito, Alessandro ; Alessandro Granito</contributor><creatorcontrib>Wu, Dongyu ; Zhang, Guangcong ; Ma, Jiamei ; Wu, Hongfen ; Xiong, Ju ; Huang, Xiaoxi ; Tian, Yuanyuan ; Deng, Taozhi ; Han, Xiangyang ; Sun, Xiaoning ; Xiang, Tian ; Yu, Xiangnan ; Jiang, Xuemei ; Granito, Alessandro ; Alessandro Granito</creatorcontrib><description>Background. Accumulating evidence has suggested that Nei-like DNA glycosylase 3 (NEIL3) is associated with human tumors. However, there are few studies on the role of NEIL3 in hepatocellular carcinoma (HCC). The aim of this study was to investigate the expression profile of NEIL3 and its clinical relevance in HCC. Materials and Methods. A total of 130 HCC and corresponding nontumor tissues were collected to perform immunohistochemistry (IHC). The clinical relevance and prognostic value of NEIL3 in HCC were analyzed by the chi-square test, Kaplan–Meier analysis, the Cox proportional hazard model, and nomogram. Results. IHC showed that the NEIL3 protein level was remarkably upregulated in tumor tissues compared with nontumor tissues (fold change = 1.24; P<0.001). High NEIL3 expression was significantly correlated with BCLC stage (P=0.004) and TNM stage (P=0.005). Overall survival (OS) and disease-free survival (DFS) rates in the high NEIL3 expression group were significantly worse than those in the low NEIL3 expression group (P=0.007 and P=0.004, respectively). Furthermore, subgroup analysis showed that high NEIL3 expression predicted worse OS and DFS for HCC patients with advanced TNM stage, poorly differentiated tumor, HBsAg positive, or cirrhosis. Multivariate analysis and the prognostic nomograms revealed that tumor NEIL3 level may serve as a promising prognostic indicator for OS and DFS in HCC patients. Conclusion. Our findings suggested that NEIL3 might be a potential prognosis assessment marker and therapeutic target for HCC patients.</description><identifier>ISSN: 1687-8450</identifier><identifier>EISSN: 1687-8450</identifier><identifier>DOI: 10.1155/2021/1301671</identifier><identifier>PMID: 34659404</identifier><language>eng</language><publisher>Egypt: Hindawi</publisher><subject>Analysis ; Antibodies ; Antigens ; Cancer ; Cancer therapies ; DNA ; Genetic aspects ; Health aspects ; Hepatoma ; Immunohistochemistry ; Liver cancer ; Liver cirrhosis ; Medical prognosis ; Medical research ; Medicine, Experimental ; Metastasis ; Nomograms ; Patients ; Prognosis ; Software ; Thymus gland ; Tumors</subject><ispartof>Journal of oncology, 2021, Vol.2021, p.1301671-11</ispartof><rights>Copyright © 2021 Dongyu Wu et al.</rights><rights>COPYRIGHT 2021 John Wiley & Sons, Inc.</rights><rights>Copyright © 2021 Dongyu Wu et al. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright © 2021 Dongyu Wu et al. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c504t-e02f04f32a925e9776392cdf02666192aeb5c8be6cabff246d18426a64d7b773</citedby><cites>FETCH-LOGICAL-c504t-e02f04f32a925e9776392cdf02666192aeb5c8be6cabff246d18426a64d7b773</cites><orcidid>0000-0001-9672-9418 ; 0000-0001-6690-6217 ; 0000-0001-9238-2285 ; 0000-0002-9463-7103 ; 0000-0001-6945-229X ; 0000-0003-2512-3157 ; 0000-0003-1739-3579 ; 0000-0002-5851-1554 ; 0000-0002-5928-738X ; 0000-0002-3379-1297 ; 0000-0003-4329-2931 ; 0000-0002-0172-3118 ; 0000-0003-1571-552X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8519696/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8519696/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,4010,27900,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34659404$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Granito, Alessandro</contributor><contributor>Alessandro Granito</contributor><creatorcontrib>Wu, Dongyu</creatorcontrib><creatorcontrib>Zhang, Guangcong</creatorcontrib><creatorcontrib>Ma, Jiamei</creatorcontrib><creatorcontrib>Wu, Hongfen</creatorcontrib><creatorcontrib>Xiong, Ju</creatorcontrib><creatorcontrib>Huang, Xiaoxi</creatorcontrib><creatorcontrib>Tian, Yuanyuan</creatorcontrib><creatorcontrib>Deng, Taozhi</creatorcontrib><creatorcontrib>Han, Xiangyang</creatorcontrib><creatorcontrib>Sun, Xiaoning</creatorcontrib><creatorcontrib>Xiang, Tian</creatorcontrib><creatorcontrib>Yu, Xiangnan</creatorcontrib><creatorcontrib>Jiang, Xuemei</creatorcontrib><title>Upregulation of Nei-Like DNA Glycosylase 3 Predicts Poor Prognosis in Hepatocellular Carcinoma</title><title>Journal of oncology</title><addtitle>J Oncol</addtitle><description>Background. Accumulating evidence has suggested that Nei-like DNA glycosylase 3 (NEIL3) is associated with human tumors. However, there are few studies on the role of NEIL3 in hepatocellular carcinoma (HCC). The aim of this study was to investigate the expression profile of NEIL3 and its clinical relevance in HCC. Materials and Methods. A total of 130 HCC and corresponding nontumor tissues were collected to perform immunohistochemistry (IHC). The clinical relevance and prognostic value of NEIL3 in HCC were analyzed by the chi-square test, Kaplan–Meier analysis, the Cox proportional hazard model, and nomogram. Results. IHC showed that the NEIL3 protein level was remarkably upregulated in tumor tissues compared with nontumor tissues (fold change = 1.24; P<0.001). High NEIL3 expression was significantly correlated with BCLC stage (P=0.004) and TNM stage (P=0.005). Overall survival (OS) and disease-free survival (DFS) rates in the high NEIL3 expression group were significantly worse than those in the low NEIL3 expression group (P=0.007 and P=0.004, respectively). Furthermore, subgroup analysis showed that high NEIL3 expression predicted worse OS and DFS for HCC patients with advanced TNM stage, poorly differentiated tumor, HBsAg positive, or cirrhosis. Multivariate analysis and the prognostic nomograms revealed that tumor NEIL3 level may serve as a promising prognostic indicator for OS and DFS in HCC patients. Conclusion. Our findings suggested that NEIL3 might be a potential prognosis assessment marker and therapeutic target for HCC patients.</description><subject>Analysis</subject><subject>Antibodies</subject><subject>Antigens</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>DNA</subject><subject>Genetic aspects</subject><subject>Health aspects</subject><subject>Hepatoma</subject><subject>Immunohistochemistry</subject><subject>Liver cancer</subject><subject>Liver cirrhosis</subject><subject>Medical prognosis</subject><subject>Medical research</subject><subject>Medicine, Experimental</subject><subject>Metastasis</subject><subject>Nomograms</subject><subject>Patients</subject><subject>Prognosis</subject><subject>Software</subject><subject>Thymus gland</subject><subject>Tumors</subject><issn>1687-8450</issn><issn>1687-8450</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>RHX</sourceid><sourceid>BENPR</sourceid><recordid>eNp9ks9vFCEYhonR2Fq9eTYkXkx0LL8ZLiabVVuTTe2hXiUMA1vqLGxhRrP_vUx2rdVDT0B48nx54QXgJUbvMeb8lCCCTzFFWEj8CBxj0cqmZRw9vrc_As9KuUFIMKTEU3BEmeCKIXYMvn_bZreeBjOGFGHy8MKFZhV-OPjxYgHPhp1NZTeY4iCFl9n1wY4FXqaU6ymtYyqhwBDhuduaMVk3DFWV4dJkG2LamOfgiTdDcS8O6wm4-vzpannerL6efVkuVo3liI2NQ8Qj5ikxinCnpBRUEdt7RIQQWBHjOm7bzglrOu8JEz1uGRFGsF52UtIT8GGv3U7dxvXWxTGbQW9z2Ji808kE_e9NDNd6nX7qlmMllKiCNwdBTreTK6PehDLHMdGlqWjCW0ox4pJU9PV_6E2acqzpZooIpoSgf6m1GZwO0ac6185SvagDW8Yklg9TLeWcE6oq9W5P2ZxKyc7fBcNIzx3Qcwf0oQMVf3X_Me7gP59egbd74DrE3vwKD-t-A-s_tns</recordid><startdate>2021</startdate><enddate>2021</enddate><creator>Wu, Dongyu</creator><creator>Zhang, Guangcong</creator><creator>Ma, Jiamei</creator><creator>Wu, Hongfen</creator><creator>Xiong, Ju</creator><creator>Huang, Xiaoxi</creator><creator>Tian, Yuanyuan</creator><creator>Deng, Taozhi</creator><creator>Han, Xiangyang</creator><creator>Sun, Xiaoning</creator><creator>Xiang, Tian</creator><creator>Yu, Xiangnan</creator><creator>Jiang, Xuemei</creator><general>Hindawi</general><general>John Wiley & Sons, Inc</general><general>Hindawi Limited</general><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-9672-9418</orcidid><orcidid>https://orcid.org/0000-0001-6690-6217</orcidid><orcidid>https://orcid.org/0000-0001-9238-2285</orcidid><orcidid>https://orcid.org/0000-0002-9463-7103</orcidid><orcidid>https://orcid.org/0000-0001-6945-229X</orcidid><orcidid>https://orcid.org/0000-0003-2512-3157</orcidid><orcidid>https://orcid.org/0000-0003-1739-3579</orcidid><orcidid>https://orcid.org/0000-0002-5851-1554</orcidid><orcidid>https://orcid.org/0000-0002-5928-738X</orcidid><orcidid>https://orcid.org/0000-0002-3379-1297</orcidid><orcidid>https://orcid.org/0000-0003-4329-2931</orcidid><orcidid>https://orcid.org/0000-0002-0172-3118</orcidid><orcidid>https://orcid.org/0000-0003-1571-552X</orcidid></search><sort><creationdate>2021</creationdate><title>Upregulation of Nei-Like DNA Glycosylase 3 Predicts Poor Prognosis in Hepatocellular Carcinoma</title><author>Wu, Dongyu ; Zhang, Guangcong ; Ma, Jiamei ; Wu, Hongfen ; Xiong, Ju ; Huang, Xiaoxi ; Tian, Yuanyuan ; Deng, Taozhi ; Han, Xiangyang ; Sun, Xiaoning ; Xiang, Tian ; Yu, Xiangnan ; Jiang, Xuemei</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c504t-e02f04f32a925e9776392cdf02666192aeb5c8be6cabff246d18426a64d7b773</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Analysis</topic><topic>Antibodies</topic><topic>Antigens</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>DNA</topic><topic>Genetic aspects</topic><topic>Health aspects</topic><topic>Hepatoma</topic><topic>Immunohistochemistry</topic><topic>Liver cancer</topic><topic>Liver cirrhosis</topic><topic>Medical prognosis</topic><topic>Medical research</topic><topic>Medicine, Experimental</topic><topic>Metastasis</topic><topic>Nomograms</topic><topic>Patients</topic><topic>Prognosis</topic><topic>Software</topic><topic>Thymus gland</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wu, Dongyu</creatorcontrib><creatorcontrib>Zhang, Guangcong</creatorcontrib><creatorcontrib>Ma, Jiamei</creatorcontrib><creatorcontrib>Wu, Hongfen</creatorcontrib><creatorcontrib>Xiong, Ju</creatorcontrib><creatorcontrib>Huang, Xiaoxi</creatorcontrib><creatorcontrib>Tian, Yuanyuan</creatorcontrib><creatorcontrib>Deng, Taozhi</creatorcontrib><creatorcontrib>Han, Xiangyang</creatorcontrib><creatorcontrib>Sun, Xiaoning</creatorcontrib><creatorcontrib>Xiang, Tian</creatorcontrib><creatorcontrib>Yu, Xiangnan</creatorcontrib><creatorcontrib>Jiang, Xuemei</creatorcontrib><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Nursing & Allied Health Premium</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wu, Dongyu</au><au>Zhang, Guangcong</au><au>Ma, Jiamei</au><au>Wu, Hongfen</au><au>Xiong, Ju</au><au>Huang, Xiaoxi</au><au>Tian, Yuanyuan</au><au>Deng, Taozhi</au><au>Han, Xiangyang</au><au>Sun, Xiaoning</au><au>Xiang, Tian</au><au>Yu, Xiangnan</au><au>Jiang, Xuemei</au><au>Granito, Alessandro</au><au>Alessandro Granito</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Upregulation of Nei-Like DNA Glycosylase 3 Predicts Poor Prognosis in Hepatocellular Carcinoma</atitle><jtitle>Journal of oncology</jtitle><addtitle>J Oncol</addtitle><date>2021</date><risdate>2021</risdate><volume>2021</volume><spage>1301671</spage><epage>11</epage><pages>1301671-11</pages><issn>1687-8450</issn><eissn>1687-8450</eissn><abstract>Background. Accumulating evidence has suggested that Nei-like DNA glycosylase 3 (NEIL3) is associated with human tumors. However, there are few studies on the role of NEIL3 in hepatocellular carcinoma (HCC). The aim of this study was to investigate the expression profile of NEIL3 and its clinical relevance in HCC. Materials and Methods. A total of 130 HCC and corresponding nontumor tissues were collected to perform immunohistochemistry (IHC). The clinical relevance and prognostic value of NEIL3 in HCC were analyzed by the chi-square test, Kaplan–Meier analysis, the Cox proportional hazard model, and nomogram. Results. IHC showed that the NEIL3 protein level was remarkably upregulated in tumor tissues compared with nontumor tissues (fold change = 1.24; P<0.001). High NEIL3 expression was significantly correlated with BCLC stage (P=0.004) and TNM stage (P=0.005). Overall survival (OS) and disease-free survival (DFS) rates in the high NEIL3 expression group were significantly worse than those in the low NEIL3 expression group (P=0.007 and P=0.004, respectively). Furthermore, subgroup analysis showed that high NEIL3 expression predicted worse OS and DFS for HCC patients with advanced TNM stage, poorly differentiated tumor, HBsAg positive, or cirrhosis. Multivariate analysis and the prognostic nomograms revealed that tumor NEIL3 level may serve as a promising prognostic indicator for OS and DFS in HCC patients. Conclusion. Our findings suggested that NEIL3 might be a potential prognosis assessment marker and therapeutic target for HCC patients.</abstract><cop>Egypt</cop><pub>Hindawi</pub><pmid>34659404</pmid><doi>10.1155/2021/1301671</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0001-9672-9418</orcidid><orcidid>https://orcid.org/0000-0001-6690-6217</orcidid><orcidid>https://orcid.org/0000-0001-9238-2285</orcidid><orcidid>https://orcid.org/0000-0002-9463-7103</orcidid><orcidid>https://orcid.org/0000-0001-6945-229X</orcidid><orcidid>https://orcid.org/0000-0003-2512-3157</orcidid><orcidid>https://orcid.org/0000-0003-1739-3579</orcidid><orcidid>https://orcid.org/0000-0002-5851-1554</orcidid><orcidid>https://orcid.org/0000-0002-5928-738X</orcidid><orcidid>https://orcid.org/0000-0002-3379-1297</orcidid><orcidid>https://orcid.org/0000-0003-4329-2931</orcidid><orcidid>https://orcid.org/0000-0002-0172-3118</orcidid><orcidid>https://orcid.org/0000-0003-1571-552X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1687-8450 |
| ispartof | Journal of oncology, 2021, Vol.2021, p.1301671-11 |
| issn | 1687-8450 1687-8450 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8519696 |
| source | Wiley Online Library Open Access; PubMed Central; Alma/SFX Local Collection; EZB Electronic Journals Library; PubMed Central Open Access |
| subjects | Analysis Antibodies Antigens Cancer Cancer therapies DNA Genetic aspects Health aspects Hepatoma Immunohistochemistry Liver cancer Liver cirrhosis Medical prognosis Medical research Medicine, Experimental Metastasis Nomograms Patients Prognosis Software Thymus gland Tumors |
| title | Upregulation of Nei-Like DNA Glycosylase 3 Predicts Poor Prognosis in Hepatocellular Carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T18%3A38%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Upregulation%20of%20Nei-Like%20DNA%20Glycosylase%203%20Predicts%20Poor%20Prognosis%20in%20Hepatocellular%20Carcinoma&rft.jtitle=Journal%20of%20oncology&rft.au=Wu,%20Dongyu&rft.date=2021&rft.volume=2021&rft.spage=1301671&rft.epage=11&rft.pages=1301671-11&rft.issn=1687-8450&rft.eissn=1687-8450&rft_id=info:doi/10.1155/2021/1301671&rft_dat=%3Cgale_pubme%3EA683555239%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2582649663&rft_id=info:pmid/34659404&rft_galeid=A683555239&rfr_iscdi=true |